Our findings that SOD2, but not SOD1 and SOD3, exhibited low baseline toxicity in the absence of asparaginase is in line with the observation that SOD2 inhibition does not dramatically change the ROS levels in cancer cells such as leukemia cells, which collectively suggests the activation of other redox pathways to compensate.31,32. The gene discussed is SOD2; the disease is cancer.